Fusion Antibodies Plc (GB:FAB) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fusion Antibodies Plc has announced an expansion of their collaboration with the National Cancer Institute to include the humanisation of camelid nanobodies, which shows promise for CAR-T therapy applications. The company, known for its work in pre-clinical antibody discovery and engineering, aims to support the NCI in advancing these therapies toward clinical success. Fusion Antibodies, established in 2001 and listed on AIM since 2017, offers a suite of services to aid in the development of therapeutic drugs and diagnostic applications.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.